Takayoshi Shimohata

Prof. Takayoshi Shimohata

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Clinical and Experimental Neuroimmunology
Verified
Journal Article
Open access
PDF file
TSTakayoshi Shimohata
Takayoshi Shimohata
Neuromuscular manifestations of new coronavirus disease 2019 (COVID‐19) infection are frequent, and include dizziness, headache, myopathy, and olfactory and gustatory disturbances. Patients with acute central nervous system disorders, such as delirium, impaired consciousness, stroke and convulsive seizures, have a high mortality rate. The encephalitis/encephalopathy that causes consciousness disturbance and seizures can be classified into three conditions, including direct infection with the SARS‐CoV‐2 virus, encephalopathy caused by central nervous system damage secondary to systemic hypercytokinemia (cytokine storm) and autoimmune‐mediated encephalitis that occurs after infection. The sequelae, called post‐acute COVID‐19 syndrome or long COVID, include neuromuscular manifestations, such as anxiety, depression, sleep disturbance, muscle weakness, brain fog and cognitive impairment. It is desirable to establish diagnostic criteria and treatment for these symptoms. Vaccine‐induced thrombotic thrombocytopenia, Guillain–Barré syndrome, bilateral facial paralysis, encephalitis and opsoclonus‐myoclonus syndrome have been reported as adverse reactions after the COVID‐19 vaccine, although these are rare.

14 April 2020 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
PDF file
KFKimiharu Fuseya
Kimiharu Fuseya
AKAkio Kimura
Akio Kimura
NYNobuaki Yoshikura
Nobuaki Yoshikura
MYMegumi Yamada
Megumi Yamada
YHYuichi Hayashi
Yuichi Hayashi
TSTakayoshi Shimohata
Takayoshi Shimohata

29 March 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AKAkio Kimura
Akio Kimura
ATAkira Takekoshi
Akira Takekoshi
TSTakayoshi Shimohata
Takayoshi Shimohata
Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy (GFAP-A) is a type of autoimmune corticosteroid-responsive meningoencephalitis that occurs with or without myelitis. Movement disorders have been reported in GFAP-A patients but have not been characterized. In this study, we examined the characteristics of movement disorders in GFAP-A patients. We retrospectively reviewed clinical data from 87 consecutive patients with GFAP-A attending Gifu University Hospital in Japan. We compared the demographics, clinical features, cerebrospinal fluid characteristics, and neuroimaging findings from patients with and without movement disorders. Seventy-four patients (85%) had movement disorders, including ataxia (49%), tremor (45%), myoclonus (37%), dyskinesia (2%), opsoclonus (2%), rigidity (2%), myokymia (1%), and choreoathetosis (1%). GFAP-A patients with movement disorders were significantly older than those without. Movement disorders are therefore common in GFAP-A patients, and the main types of movement disorders observed in this population were ataxia, tremor, and myoclonus. These abnormal movements can serve as clinical features that facilitate the early diagnosis of GFAP-A. Elderly GFAP-A patients are more likely to have movement disorder complications than younger patients.

1 June 2023 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
MAMegumi Abe
Megumi Abe
HYHiroaki Yaguchi
Hiroaki Yaguchi
AKAkihiko Kudo
Akihiko Kudo
ANAzusa Nagai
Azusa Nagai
SSShinichi Shirai
Shinichi Shirai
IYIchiro Yabe
Ichiro Yabe

30 May 2024 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
SMSatoko Miyatake
Satoko Miyatake
HDHiroshi Doi
Hiroshi Doi
HYHiroaki Yaguchi
Hiroaki Yaguchi
EKEriko Koshimizu
Eriko Koshimizu
NKNaoki Kihara
Naoki Kihara
NMNaomichi Matsumoto
Naomichi Matsumoto
Background: Although pure GAA expansion is considered pathogenic in SCA27B, non-GAA repeat motif is mostly mixed into longer repeat sequences. This study aimed to unravel the complete sequencing ofFGF14repeat expansion to elucidate its repeat motifs and pathogenicity.Methods: We screenedFGF14repeat expansion in a Japanese cohort of 460 molecularly undiagnosed adult-onset cerebellar ataxia patients and 1022 controls, together with 92 non-Japanese controls, and performed nanopore sequencing ofFGF14repeat expansion.Results: In the Japanese population, the GCA motif was predominantly observed as the non-GAA motif, whereas the GGA motif was frequently detected in non-Japanese controls. The 5′-common flanking variant was observed in all Japanese GAA repeat alleles within normal length, demonstrating its meiotic stability against repeat expansion. In both patients and controls, pure GAA repeat was up to 400 units in length, whereas non-pathogenic GAA-GCA repeat was larger, up to 900 units, but they evolved from different haplotypes, as rs534066520, located just upstream of the repeat sequence, completely discriminated them. Both (GAA)≥250and (GAA)≥200were enriched in patients, whereas (GAA-GCA)≥200was similarly observed in patients and controls, suggesting the pathogenic threshold of (GAA)≥200for cerebellar ataxia. We identified 14 patients with SCA27B (3.0%), but their single-nucleotide polymorphism genotype indicated different founder alleles between Japanese and Caucasians. The low prevalence of SCA27B in Japanese may be due to the lower allele frequency of (GAA)≥250in the Japanese population than in Caucasians (0.15% vs 0.32%–1.26%).Conclusions: FGF14repeat expansion has unique features of pathogenicity and allelic origin, as revealed by a single ethnic study.

30 April 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
YOYoya Ono
Yoya Ono
KTKoh Tadokoro
Koh Tadokoro
TYTaijun Yunoki
Taijun Yunoki
TYToru Yamashita
Toru Yamashita
DSDaisuke Sato
Daisuke Sato
TSTakayoshi Shimohata
Takayoshi Shimohata